Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, Sarepta will pay Arrowhead $500 million upfront and make a $325 million equity investment to gain access to Arrowhead's gene silencing technologies, which are focused on developing treatments for rare genetic diseases affecting muscles, the central nervous system, and lungs.

Market Domination Co-hosts Julie Hyman and Josh Lipton break down the companies stock reactions to the news.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written by Angel Smith